Welcome to our dedicated page for Verastem SEC filings (Ticker: VSTM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Verastem, Inc. filings document a Nasdaq-listed biopharmaceutical company with common stock trading under VSTM and a business focused on RAS/MAPK pathway-driven cancers. Its 8-K reports furnish corporate presentations, financial-result releases, strategic updates, clinical data disclosures, and Regulation FD materials for AVMAPKI FAKZYNJA CO-PACK, RAMP clinical programs, and VS-7375.
The company’s SEC records also cover capital-structure activity, including common stock and pre-funded warrant offerings, and proxy disclosures for board matters, executive compensation, equity awards, and shareholder voting. These filings frame Verastem’s commercialization, pipeline development, governance, financing, and public-company reporting obligations.
Verastem Oncology reported updated early-stage results from its RAMP 205 Phase 1b/2a trial in first-line metastatic pancreatic ductal adenocarcinoma. In 29 patients treated at the recommended Phase 2 dose with avutometinib plus defactinib and standard chemotherapy, 90% had metastatic disease at diagnosis.
As of a June 5, 2026 data cutoff and 9.8 months median follow-up, the combination showed an 86% overall survival rate at 6 months, a 68% progression-free survival rate at 6 months, and a confirmed objective response rate of 52% (15 of 29 patients). Most patients (83%) experienced tumor shrinkage, nine remained on treatment, and no new safety signals were observed.
The company also began dosing the first patient in TARGET-D 201, a Phase 2 registration-directed trial of VS-7375, an investigational oral KRAS G12D inhibitor, given at 900 mg daily as monotherapy and with full-dose cetuximab in second-line metastatic pancreatic cancer.
BAILEY MICHAEL P reported acquisition or exercise transactions in this Form 4 filing.
Verastem, Inc. director Michael P. Bailey reported an equity award of 108,000 shares of Common Stock in the form of restricted stock units at no cash cost. The grant consists of 36,000 RSUs as an annual grant and 72,000 RSUs as an initial grant under Verastem's Amended and Restated 2021 Equity Incentive Plan.
The 36,000 annual grant RSUs vest in twelve monthly installments from June 2026 through May 2027, tied to continued board service. The 72,000 initial grant RSUs vest in twelve quarterly installments starting on May 21, 2026, and are scheduled to fully vest three years from that date, also contingent on continued service. Following this award, Bailey directly holds 108,000 shares/RSUs.
Verastem, Inc. director Michael P. Bailey has filed an initial SEC Form 3 as a reporting person for the company. The filing does not report any insider transactions and shows no derivative positions, serving as a baseline disclosure of his status as a director.
Tollefson Karin Anna reported acquisition or exercise transactions in this Form 4 filing.
Verastem, Inc. director Karin Anna Tollefson received a grant of 36,000 restricted stock units (RSUs) of Common Stock. The RSUs were awarded under Verastem’s Amended and Restated 2021 Equity Incentive Plan and require her continued service as a director to vest.
The RSUs vest in 12 substantially equal monthly installments, with the first 11 vesting on the last day of each month from June 2026 through April 2027. The final installment vests on the earlier of the day before Verastem’s 2027 Annual Meeting of Stockholders or May 31, 2027. After this grant, Tollefson directly holds 52,666 shares of Verastem Common Stock, including the granted RSUs.
Stuglik Brian M reported acquisition or exercise transactions in this Form 4 filing.
Verastem, Inc. director Brian M. Stuglik received an equity grant of 36,000 restricted stock units (RSUs) of Common Stock. The RSUs were granted at no cash cost as director compensation and will vest in twelve substantially equal monthly installments from late June 2026 through April 2027, with the final installment vesting on the earlier of the day before the 2027 Annual Meeting of Stockholders or May 31, 2027, subject to continued board service. Following this award, Stuglik holds 137,147 shares of Verastem Common Stock directly.
Rowinsky Eric K reported acquisition or exercise transactions in this Form 4 filing.
Verastem, Inc. director Eric K. Rowinsky received a grant of 36,000 restricted stock units (RSUs). The grant was made at a price of $0.00 per share under Verastem’s Amended and Restated 2021 Equity Incentive Plan, reflecting stock-based compensation rather than an open-market purchase.
Each RSU represents the right to receive one share of common stock. The RSUs vest in twelve substantially equal monthly installments from the end of June 2026 through April 2027, with the final installment vesting on the earlier of the day before the 2027 annual stockholders’ meeting or May 31, 2027, contingent on his continued board service. Following this award, Rowinsky directly holds 52,666 shares of Verastem common stock.
ROBERTSON MICHELLE reported acquisition or exercise transactions in this Form 4 filing.
Verastem, Inc. director Michelle Robertson received a grant of 36,000 restricted stock units (RSUs) of Common Stock as equity compensation. The award was granted at no cash cost per share and is structured to vest over time rather than all at once.
The RSUs were granted under Verastem's Amended and Restated 2021 Equity Incentive Plan, with each RSU representing the right to receive one share of Common Stock. The units vest in twelve substantially equal monthly installments from the end of June 2026 through April 2027, with the final installment vesting on the earlier of the day before the 2027 Annual Meeting of Stockholders or May 31, 2027, subject to her continued board service. After this grant, Robertson directly holds 52,666 shares of Verastem common stock.
Kapur Anil reported acquisition or exercise transactions in this Form 4 filing.
Verastem, Inc. director Anil Kapur received a grant of 36,000 restricted stock units (RSUs). The award was made at no cash cost per share and increased his directly held common stock-related position to 52,666 shares as reported after the transaction.
The RSUs were granted under Verastem’s Amended and Restated 2021 Equity Incentive Plan. Each RSU represents the right to receive one share of common stock, vesting in twelve substantially equal monthly installments from late June 2026 through April 2027, with the final installment vesting by May 31, 2027, if he continues serving as a director.
Bunn Paul A. reported acquisition or exercise transactions in this Form 4 filing.
Verastem, Inc. director Paul A. Bunn received an equity grant of 36,000 shares of Common Stock in the form of restricted stock units (RSUs) under the company’s Amended and Restated 2021 Equity Incentive Plan. This is a compensation-related award, not an open-market purchase.
Each RSU represents one share of Common Stock. The award vests in twelve substantially equal monthly installments from the end of June 2026 through April 2027, with the final installment vesting on the earlier of the day before the 2027 annual stockholder meeting or May 31, 2027, subject to his continued board service. After this grant, Bunn holds 44,333 shares directly.